Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Research and Innovation Action · Running

STRONG-UR STRategies for Optimised bioprinting of Next Generation tissues for URethral regeneration and translation (STRONG-UR)

Coordinator
Aalborg Universitet, Denmark
Runs
1 November 2024 to 31 October 2028
Status
Running
EU funding
€7.8m
Total cost
€7.8m
Partners
12 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101191695

What the project is doing

In the project's own words, from its summary on CORDIS.

STRONG-UR aims to revolutionise surgical tissue reconstruction by producing next-generation bioprinted tubular tissue constructs, focusing on urethral tissue engineering. Urethral strictures affect approximately 0.6% of the male population, leading to persistent physical and psychological impairment in patients and imposing a significant economic burden on healthcare systems. The lack of effective techniques to heal and repair diseased urethras emphasises the urgent need to invest in innovative regenerative approaches.

In this direction, bioprinting offers promising prospects through the production of customised tissue constructs with controlled cell composition and architecture. However, there is still a significant gap between laboratory studies and clinical application, which is why there is currently no reliable technology available for clinical use. STRONG-UR includes the development of modular, scalable bioprinter components and bioinks to bridge the current gap.

The bioinks comprise smart hydrogels customisable to personalised urethral constructs, supporting desired cellular functions and enabling non-invasive monitoring for real-time treatment assessment. Two different approaches are proposed: a single stage in situ bioprinting approach for accelerated clinical translation and a multistage approach using GMP-manufactured components to induce vascularisation and promote tissue healing.

In addition, a novel bioprinted in vitro urethral model is proposed as a human-based testing platform for more ethical and reliable preclinical assessments. The project is in line with EU health policy, addressing unmet clinical needs and supports a Europe fit for the digital age. With a 12-partner consortium composed of scientists, clinicians, and companies contributing to the whole value chain, supported by a state-of-the-art infrastructure and a proven track record of successful projects in this field, STRONG-UR represents the best team to deliver this ground-breaking work.

Topics

Who is involved

OrganisationCityCountryRole
Aalborg UniversitetAalborgDenmarkCoordinator
4tissueGentBelgiumParticipant
MetaSint-Joost-Ten-NodeBelgiumParticipant
Universiteit GentGentBelgiumParticipant
Region Nordjylland (north Denmark Region)AalborgDenmarkParticipant
Brinter OyTurkuFinlandParticipant
Tampereen Korkeakoulusaatio SrTampereFinlandParticipant
Universita Cattolica Del Sacro CuoreMilanoItalyParticipant
Stichting European Urological FoundationArnhemNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Wellspect ABMolndalSwedenParticipant
Adbioink Biyosistem Teknoloji Anonim SirketiKocaeliTürkiyeParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI